wellrank.ai
Obesity Action Coalition logo

Obesity Action Coalition

First cited by AI Jun 29, 2026
obesityaction.org

Surfaced organically in AI answers about compounded glp-1s. Not yet profiled.

Obesity Action Coalition is losing the AEO war.

Not cited in a single tracked AI answer since Jul 3, 2026, down from a peak of 2% visibility in compounded glp-1s on Jun 29, 2026. This page stays public, and recovery shows here the day it happens.

AI Visibility

Visibility trend

Compounded GLP-1s, daily share of AI answers mentioning Obesity Action Coalition, through Jul 6, 2026.

0.0%

Last cited Jul 3, 2026 · peak 2% on Jun 29

By engine

Where Obesity Action Coalition is strong, and where it is invisible.

  • No engine data yet.

Mention sentiment

Tone of AI mentions across all tracked answers.

  • 0 positive mentions
  • 0 neutral
  • 1 mixed or cautious

Recent AI answers mentioning Obesity Action Coalition

PerplexityJun 29, 2026, 15:03 UTC
My insurance denied Wegovy. Are compounded GLP-1s my best option?

Compounded GLP-1s are not your best option for long-term treatment if you simply want a cheaper alternative to denied Wegovy, due to significant safety risks and lack of FDA approval; they are only appropriate if a documented medical need for a custom dose cannot be met by brand-name versions [1][2]. However, if you are uninsured, underinsured, or have been denied coverage, compounded versions may be the only realistic option available to you, as they cost roughly $250–$400 per month compared to over $1,000 for brand-name drugs [3][7]. Key Risks and Limitations to Consider Safety and Quality Uncertainties: Compounded GLP-1s are not reviewed by the FDA for safety, quality, or effectiveness, meaning dosing, purity, and consistency can vary from batch to batch [1][2]. Professional Recommendations: Leading medical organizations, including the American Diabetes Association, Obesity Medicine Association, and Obesity Action Coalition, have recommended against or advised caution regarding non-FDA-approved compounded GLP-1s [1][4]. Regulatory Changes: Since shortages of semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro) have been resolved (as of 2025), pharmacies are no longer allowed to regularly make copies of these commercially available drugs [5][7]. Exception for Medical Need: Compounding is still permitted if a patient has a specific medical need (e.g., a non-standard dose) that cannot be met by an FDA-approved product, but it cannot be used just for cost or convenience [2][5]. Recommended Alternatives and Actions Instead of immediately choosing compounded drugs, consider these steps: File an Insurance Appeal: Request a formal appeal from your insurance provider to cover Wegovy; denials can sometimes be overturned with a physician's letter of medical necessity [3]. Check Manufacturer Savings Programs: Contact Wegovy’s manufacturer (Novo Nordisk) for potential patient savings cards or copay assistance programs [3]. Consult Your Healthcare Team: Discuss with your doctor whether a brand-name alternative (like Ozempic or Mounjaro) might be covered, or if a custom medical need truly exists that justifies the risks of compounding [5]. Avoid "Fake" Online Shops: If you must use compounding, ensure you use a legitimate, state-licensed compounding pharmacy and verify their sourcing of raw materials to avoid counterfeit products [8]. Specific Brands to Consider: Brand-Name Wegovy, Ozempic, Mounjaro: These are the safest, FDA-approved options, though expensive. Legitimate Compounding Pharmacies: If you are forced to use compounded versions due to cost, choose only those with verified licenses and transparent sourcing [8]. Given the resolution of shortages and professional warnings, compounded GLP-1s should be a temporary or last-resort measure, not your primary long-term strategy, unless you have no other way to access treatment [1][5].

Mentioned in position 3 of 4

Read full answer with sources →

Competitive Landscape

Obesity Action Coalition vs the brands AI recommends alongside it

The real competitive set in Compounded GLP-1s: brands the engines name in the same answers, ranked on the latest day.

BrandRankAI visibility
Obesity Action Coalition logo
Obesity Action CoalitionThis brand
0.0%
Novo Nordisk logo
Novo Nordisk

1 shared answers

#3
33.3%

Email me when overtakes Obesity Action Coalition

One email the day the ranks flip. Nothing else.

Sources cited around Obesity Action Coalition

The sites engines cite in answers mentioning this brand. Win these, win the answer.

Track Obesity Action Coalition weekly

One email a week: rank moves, new competitors, and the answers that changed. No noise.

Work at Obesity Action Coalition? Get your AI Visibility Audit.

See every buyer intent question your customers ask AI, which ones you are losing, who wins them instead, and the exact sources driving those answers. You will finally understand your buyer intent and what Propel would do to win it.